CEBPA and acute myeloid leukemia: miR-182 expression is highly elevated in acute myeloid leukemia (AML) patients with C/EBPα mutations disrupting its C-terminal DNA binding domain and is recommended as a prognostic marker in cytogenetically high-risk AML patients (Wurm et al., 2017).